康弘药业：自研KH631眼用注射液新增适应症获批临床

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s subsidiary, Chengdu Hongji Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its KH631 eye injection for the treatment of Diabetic Macular Edema (DME) [1] Group 1 - The approved indication for KH631 is specifically for Diabetic Macular Edema (DME) [1]